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1. Introduction  
Janus kinases (JAKs) are a family of receptor-associated tyrosine kinases which are crucial 
for the survival and proliferation of immune and hematopoietic-derived cells. There are four 
mammalian JAKs identified to date: JAK1, JAK2, JAK3 and TYK2 (Lopez et al., 2010). JAKs 
are responsible for mediating the intracellular signaling of numerous growth factors and 
cytokines (Murray et al., 2007 & O’Shea et al., 2002). Once activated JAKs directly 
phosphorylate and activate the transcription factors signal transducers and activators of 
transcriptions (STATs) which transduce JAK signaling by translocating to the nucleus to 
modulate a subset of genes that are critical for cell proliferation and survival (Aaronson et 
al., 2002 & Levy et al., 2002). Dysregulated JAK signaling has been implicated in the 
pathogenesis of several blood-borne cancers but most notably in myeloproliferative 
neoplasms (MPNs) (Nelson et al., 2006; Lucia et al., 2011 & Patnaik et al., 2009). MPNs are 
hematological malignancies defined by the excessive proliferation of one or more myeloid-
derived cells. MPNs are classified into two clinical categories either BCR-ABL-positive 
(BCR-ABL (+)) or BCR-ABL-negative (BCR-ABL (-)) based on the presence of the BCR-ABL 
fusion protein. The major BCR-ABL (-) MPNs include polycythemia vera (PV), essential 
thrombocythemia (ET) and myelofibrosis (MF). The specific pathogenic role that JAK2 has 
in driving some of these MPNs is highlighted by the recent seminal discovery of the 
JAK2V617F mutation (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; & Levine et 
al., 2005). The JAK2V617F mutation is a somatic, gain-of function point mutation which leads 
to constitutive activation of JAK2 and subsequent downstream activation of STATs (Baxter 
et al., 2005 & James et al., 2005). Current data demonstrates that JAK2 is a disease associated 
gene involved in the pathogenesis of BCR-ABL (-) MPNs. However, it remains unclear if 
JAK2 pathway mutations are the primary drivers of sustained disease progression. New 
data is emerging that suggests that targeting the JAK-STAT pathway may have implications 
beyond the treatment of MPN and can be useful for the treatment of other hematological 
and non-hematological cancers. This review will summarize the pathogenic role of JAK-
STAT signaling in BCR-ABL (-) MPNs and introduce the potential broader implications by 
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which JAK-STAT pathway inhibition may have in treating hematological malignancies as 
well as solid tumors.  
2. Janus Kinase Family (JAKs) 
2.1 Function 
Janus kinases are a family of cytoplasmic receptor associated tyrosine kinases responsible 
for integrating the signaling of numerous growth factors and cytokines that are critical for 
hematopoiesis and immune function. There are four JAK family members; JAK1, JAK2, 
JAK3 and TYK2. JAK1, JAK2 and TYK2 are ubiquitously expressed while JAK3 expression is 
restricted to myeloid and lymphoid tissue (Valentino et al., 2006 & Ward et al., 2000 ). 
Various cytokines and growth factor receptors rely on JAKs to propagate their intracellular 
signaling cascades since many of these receptors lack intrinsic kinase activity. JAKs can be 
differentially or coordinately activated in response to various growth factor or cytokine 
stimuli (Murray, 2007). Targeted disruption of individual JAKs have been generated in an 
effort to better understand the biological non-redundant roles that JAKs have in 
development. JAK1 knock-out mice have been generated and present with a perinatal lethal 
phenotype that is characterized by severe defects in lymphopoiesis and neuronal 
development (Rodig et al., 1998). JAK3 mutations in humans have been described in patients 
with severe combined immunodeficiency (SCID), an immune disorder where major defects 
in T- and B- cell development are observed. This clinical phenotype is recapitulated in JAK3 
knock-out models where these mice manifest with SCID-like features characterized by 
impaired lymphocyte production (Nosaka et al., 1995 & Park et al., 2000). TYK2 deficiencies 
although rare have been reported, and these patients usually present with severe dermatitis 
and hyper-IgE syndrome-like symptoms (HIES). Genetic disruption studies involving TYK2 
have presented with severe defects in IL-12 signaling and impaired Th1 and Th2 mediated 
immune responses (Karaghiosoff et al., 2003). Genetic inactivation of JAK2 in mice is 
embryonically lethal due to severe anemia, confirming the critical role that JAK2 is thought 
to have in erythropoiesis (Parganas et al., 1998).  
2.2 Structure  
JAK proteins share seven homologous structural domains (JH1-JH7) each of which elicit 
distinct functional features within JAK proteins. The JAK homology domains consist of the 
C-terminus JH1 domain which is the kinase-active domain, the auto-regulatory JH2 
pseudokinase domain, the SH2-like JH3 domain and the N-terminus FERM (four-point-one, 
ezrin, radixin, and moesin) domain (JH4-JH7). Although the JH3 domain possesses a SH2-
like sequence it is unable to bind and interact with phospho-tyrosine residues and therefore 
its precise function remains unclear while the FERM domain is responsible for mediating 
the interactions of JAKs with their cognate receptors (Huang et al., 2001 & Radtke et al., 
2005). The JH2 pseudokinase domain is a unique structural feature of the JAKs that is 
otherwise absent in other kinase families. The JH2 pseudokinase domain bears high 
sequence identity to the JH1 kinase domain but is devoid of any catalytic activity and is 
thought to act as a regulatory domain through catalytic auto-inhbition (Saharinen et al., 
2000). Moreover, key activating point mutations have been identified in the JH2 
pseudokinase domain of JAK2 that are critically involved in the pathogenesis of some 
myeloproliferative neoplasms (MPNs).  
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Fig. 1. JAK Protein Domain Structure. The seven homologous JAK domains (JH1-JH7) 
conserved throughout the JAK kinase family.  
2.3 JAK-STAT signaling  
In the absence of ligand, JAKs are pre-associated with receptor monomers, upon ligand 
binding receptor dimerzation ensues leading to trans-phosphorylation and auto-activation 
of JAKs. Once activated, JAKs proceed to phosphorylate specific tyrosine residues within 
the cytoplasmic domains of growth factor receptors creating docking sites for downstream 
mediators of JAK signaling. JAKs can activate classical signaling pathways such as PI-3-
kinase and MAPK but JAKs also directly activate STATs as described above. STATs are 
latent transcription factors that are activated and phosphorylated by JAKs at specific 
tyrosine residues (Darnell J, 1997 & Benekli et al., 2003). Once phosphorylated, STAT 
monomers can then homo/hetero-dimerize through reciprocal Src homology 2 (SH2) 
interactions and translocate to the nucleus to modulate the transcription of key genes which 
promote cell growth and survival.  
 
 
Fig. 2. Ligand-Induced JAK-STAT Activation 
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3. Myeloproliferative Neoplasms (MPNs) 
3.1 Clinical biology 
MPNs are hematopoietic malignancies characterized by excessive growth of one or more 
myeloid derived cell lineages such as erythrocytes, platelets and/or granulocytes. MPNs are 
clinically grouped into either BCR-ABL (+) or BCR-ABL (-) based on the presence of the 
BCR-ABL protein, as seen in CML patients. Dysregulated JAK-STAT signaling has been 
implicated in the pathogenesis of these BCR-ABL (-) MPNs. The three most common BCR-
ABL (-) MPNs include polycythemia vera (PV), essential thrombocythemia (ET) and 
idiopathic myelofibrosis (IMF) with an estimated annual cumulative incidence of 130,000 
patients in the United States which translates into an estimated prevalence of 6.2 per 100,000 
cases (Ma et al., 2008; Mesa et al., 1999 & Ania B et al., 1994). The major clinical features of 
PV include uncontrolled growth of multiple myeloid-derived lineages with the dominating 
lineage being erythrocytes which is often reflected by an increased hematocrit and 
splenomegaly, while minor features include trilineage myeloproliferation of the bone 
marrow (Wadleigh & Tefferi, 2010). ET is characterized by an increase in both platelet size 
and number while hematocrit is unchanged. IMF is the most severe of the three MPNs and 
the major clinical criteria for diagnosis usually includes megakaryocytic proliferation 
accompanied by severe fibrosis of the bone marrow or hypercellularity of the bone marrow 
that is characterized by granulocyte proliferation (Wadleigh & Tefferi, 2010). IMF can 
manifest on its own or it can be preceded by PV or ET, post-PV or post-ET IMF has a 
variable evolution rate of roughly 25 evolutions per 1000 patients ET/PV patients 
(Passamonti et al., 2008 & Gangat et al., 2007). Furthermore, each one of these MPNs has the 
potential to progress to acute myelogenous leukemia (AML). In an unselected BCR-ABL (-) 
MPN population the overall leukemic transformation (LT) rate registered at 4.0% with MF 
having the highest transformation rate: 11.4%-MF, 4.3%-PV & 1.75% for ET (Cervantes et al., 
1991). Aberrant tyrosine kinase signaling has been implicated in the pathogenesis in the 
majority of MPNs, most notably with CML where the product of a chromosomal 
translocation results in the production of constitutively active tyrosine kinase known as the 
BCR-ABL (Druker et al., 1996). The discovery of the BCR-ABL tyrosine kinase led to the 
development of the clinically successful small molecule inhibitor, imatinib, which 
predominately targets BCR-ABL in addition to PDGF-R and KIT kinases (O’Brien et al., 
2003). The initial observation that altered tyrosine kinase signaling could single-handedly 
drive the entire pathogenesis of a disease as seen with BCR-ABL and CML hinted at the 
possibility that other altered tyrosine kinase signaling could be involved in the pathogenesis 
of these BCR-ABL (-) MPNs. 
3.2 Pathogenic role of JAK2 in BCR-ABL-negative MPNs 
Mutations in JAK2 have been implicated as a key genetic factor responsible for driving BCR-
ABL (-) MPNs and several lines of evidence highlight this finding. The major hematopoietic 
growth factors erythropoietin (Epo) and thrombopoietin (Tpo) that give rise to the myeloid 
derived cells that often over-populate PV and ET patients such as erythrocytes and platelets 
signal exclusively through JAK2. Loss of heterozygosity (LOH) on chromosome 9, where 
JAK2 is localized is observed in roughly 30% of PV patients (Kralovics et al., 2002), 
moreover, progenitor cells isolated from PV patients have routinely demonstrated an 
increased sensitivity to hematopoietic growth factors such as Epo and Tpo in ex vivo colony 
growth assays. Additionally, multiple animal models involving targeting expression of 
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JAK2 including transgenic and retroviral transduction methods leads to a MPN-like 
phenotype in vivo, further supporting a causal role for JAK2 in the pathogenesis of these 
diseases (Wernig et al., 2006)  
3.3 V617F and other JAK2-associated mutations in MPNs 
In 2005, several independent laboratories identified a unique somatic activating point 
mutation in the JAK2 gene (V617F). The JAK2V617F mutation occurs in the JH2 pseudokinase 
domain of JAK2 in exon 14 at position 617 where a valine is replaced with a phenylalanine 
which leads to constitutive activation of JAK2. The mechanism of activation of the V617F 
mutation is believed to be due to the removal of the auto-inhibitory function of the JH2 
pseudokinase domain present in JAK2. The incidence of the JAK2V617F mutation is highly 
prevalent within the BCR-ABL (-) MPN patient population particularly within PV cohorts 
where more than 95% (Wernig et al., 2006) of PV patients are positive for it while 50% of ET 
and IMF patients are positive for it (Pikman et al, 2006). Although the JAK2V617F mutation 
represents a major genetic event underlying the pathogenesis of these MPNs there is still a 
fraction of PV patients (~5%) and ET/IMF patients (~50%) that present with these MPNs but 
yet are negative for the V617F JAK2 mutation. The existence of V617F-negative MPNs 
highlights the need to identify additional JAK2 signaling components that may be involved 
in the pathogenesis of these V617F-independent MPNs. Several gain-of-function mutations 
comprised of deletions, insertions and frame-shifts have been indentified in exon 12 of JAK2 
in a small subset of V617-negative PV patients (~3%) (Scott et al., 2007). Interestingly, exon 
12 JAK2 mutations are mutually exclusive from V617F JAK2 mutations and to date have 
only been described in V617F-negative PV patients. Expression of exon 12 JAK2 mutations 
results in a PV-like phenotype in vivo that is characterized by erythrocytosis. Alternatively, 
activating point mutations in the thrombopoietin receptor (Tpo-R/c-MPL) have been 
identified in a subset of V617F-negative ET and IMF patients (5-10%). The mechanism of 
action for the MPLW515L mutation is similar to that of the V617F mutation since it also 
results in the removal of an auto-inhibitory sequence thought to be located within the 
transmembrane region of the Tpo receptor which causes spontaneous activation of 
downstream JAK2-STAT signaling (Pikman et al., 2006). The relative frequencies of these 
JAK-related mutations are summarized in figure 3 (Paradanani et al, 2011). The oncogenic 
potential of these mutations in MPN is further highlighted by their ability to induce MPN-
like phenotypes in murine bone marrow reconstitution studies. JAK2V617F expression 
induces a PV-like phenotype that presents with erythrocytosis and splenomegaly while 
(Wernig et al., 2006) MPLW515L promotes a more aggressive MF-like phenotype 
characterized by marked thrombocytopenia and severe fibrosis of the bone marrow (Pikman 
et al., 2006). Collectively, these results highlight a strong selective pressure to activate JAK-
STAT signaling in BCR-ABL-(-) MPNs and thus therapies designed to target the JAK-STAT 
signaling may be beneficial for the treatment of MPN.  
4. JAK inhibitors in clinical development  
Since the discovery of the JAK2V617F mutation in 2004 remarkable scientific progress has 
been made from bench to beside with the first JAK inhibitors being tested in humans by mid 
2007. Currently there are 36 clinical trials in the US underway evaluating various treatments 
for MPNs or investigating the molecular pathobiology underlying MPNs. The current JAK 
inhibitors are typically small molecule ATP competitive inhibitors of both wild-type and  
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Fig. 3. Allele Frequency in IMF Cohort, adapted from Chaligne R, et al. Leukemia (2008). 
Relative mutation frequency in a IMF cohort (n =603), V617F; 58%, MPLW515L; 8.1% and 
MPLW515L/V617F <1% 
mutant JAK enzymes that can be either selective JAK2 inhibitors or non-selective JAK2 
inhibitors with the latter having additional activity against other kinases besides JAK2. 
Initial clinical trials with JAK inhibitors were designed to recruit only IMF patients based on 
the biological severity of IMF compared to ET or PV, however more recently, clinical trials 
have expanded to include testing of JAK inhibitors in both PV and ET cohorts. The most 
advanced JAK inhibitor in the clinic to date is ruxolitinib (INCB018424), a pan-JAK inhibitor 
which demonstrates potent activity against JAK2 and JAK1 (Quintas-Cardama et al., 2010). 
A recent phase I/II trial (n=153) has commenced evaluating ruxolitinib for the treatment of 
IMF. While on ruxolitinib, a significant number of patients demonstrated a favorable clinical 
response including a reduction in spleen size, improvement in constitutional symptoms and 
normalization of pro-inflammatory cytokine levels. The suppression of inflammatory 
cytokines is thought to be linked to the pan inhibitory effects of ruxolitinib on both JAK1 
and JAK2 (Verstovsek et al., 2010). Given the clinical response of ruxolitinib in the treatment 
of IMF, trials have begun to evaluate the safety and efficacy of ruxolitinib in the treatment of 
PV and ET. Interestingly, these clinical responses did not correlate with JAK2V617F status 
and molecular remission of the mutant allele was absent even after two years of continued 
therapy (Verstovsek et al., 2008). The lack of effect on mutant allele burden could be due to 
direct loss of the mutant allele itself also known as “V617F-independence” that is reported 
to occur in some patients throughout the evolution of MPN (Passamonti et al., 2010). 
TG101348 is small molecule inhibitor of JAK 2 in clinical development. Results from a phase 
I/II multicenter study in IMF patients revealed that >45% of patients on TG101348 observed 
a >50% reduction in spleen size which was evident by five months but could be detected 
early two months and more than 70% of patients that presented with elevated white blood 
cell counts prior to treatment normalized (Pardanani et al., 2009). Unlike ruxolinitib, there 
was no significant decrease in serum levels of inflammatory cytokines while on therapy 
although the majority of patients did report a resolution of IMF-associated constitutional 
symptoms.  
 V617F + 
 MPLW515L + 
 ? 
 MPLW515L+V617F+  
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Compound   Company  Indication Phase NCT Trial # 
INCB18424 Incyte PV/ET/MF I/II/III NCT01445769 
TG101348 TargeGen MF I/II NCT00631462 
SB1518 S*BIO PV/ET/MF I/II NCT00745550 
CYT387 YM BIOSCIENCES MF I/II NCT00935987 
AZD1480 Astra Zeneca MF I/II NCT00910728 
LY2784544 Eli Lilly PV/ET/MF I NCT01134120 
BMS-911543 Bristol Myers-Squibb MF I NCT01236352 
Table 1. Current JAK Inhibitors in the Clinic 
5. Implications for targeting JAK-STAT signaling in additional hematological 
cancers and solid tumors 
Activating mutations in JAK2 (V617F and exon 12) in BCR-ABL (-) MPNs appear to be the 
primary mechanism by which these cells preferentially activate JAK-STAT signaling, 
however there are additional mechanisms available for cells to activate JAKs. Cells can also 
undergo chromosomal rearrangements which also lead to constitutive activation of JAKs. 
Chromosomal translocations activate JAKs by causing constitutive dimerization through 
replacement of amino terminal sequences with a fusion partner. In non-MPN hematological 
malignancies such as acute leukemias and lymphomas chromosomal rearrangements 
involving JAK2 represent another mechanism for activating JAK2. There have been seven 
fusion partners identified for JAK2, most of which lead to constitutive activation of JAK2 
signaling, these are summarized in table 2.  
 
    
Fusion Partner  Cancer Oncogenic Reference 
TEL (ETV6) T-ALL, aCML,B-ALL Yes Lacronique, 1997 
PCM1 ALL, aCML Yes Reiter, 2005 
BCR aCML Yes Greisinger, 2005  
SSBP2 B-ALL  Yes Poitras, 2008  
STRN3  ALL  Yes Mullighan, 2009  
PAX5 ALL  No  Bousquet, 2007  
SEC31-A cHL Yes VanRoosbroeck, 2011  
Table 2. Summary of JAK2 fusion partners due to chromosomal translocations involving 
chromosome 9p24. Abbreviations include-: T-ALL = T-cell acute lymphoblastic leukemia, 
aCML= atypical chronic myelogenous leukemia, B-ALL = B-cell acute lymphoblastic 
leukemia, ALL = acute lymphoblastic leukemia and cHL = classic Hodgkin lymphoma.  
5.1 Role of JAK-STAT signaling in non-MPN hematological malignancies 
Evidence is accumulating indicating dysregulated JAK-STAT signaling in various types of 
lymphomas. In classical Hodgkin lymphoma (cHL) and primary mediastinal B cell 
lymphoma (PMBL) several different mechanisms appear to be involved in the preferential 
activation of the JAK-STAT signaling network. An estimated 30% cHL patients and 35%-
45% of PMBL patients (Joos et al., 2003, 2000; Meier et al.,2009) present with genetic gains in 
chromosome band 9p24, the region where JAK2 is localized. Recently, several tumorgenic 
functions have been associated with this amplicon including JAK2-mediated increases in 
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programmed cell death 1 ligand 1 (PD-L1) expression. PD-L1 is also localized to band 9p24 
and therefore cells positive for this genetic gain can also demonstrate increased PD-L1 
expression in addition to elevated JAK 2 content. PD-L1 inhibits antitumor cytotoxic T 
lymphocyte (CTL) responses by activating its cognate inhibitor PD-1 receptor located on T-
cells, therefore PD-L1-/PD-1 interactions can promote tumorgenesis by mediating tumor 
evasiveness. A recent study showed elevated expression of PD-L1 and JAK2 in a subset of 
cHL and PMBL cell lines that were positive for the 9p24 amplicon and went on to show that 
PD-L1 expression could be augmented upon JAK2 inhibition suggesting a regulatory role 
for JAK2 in PD-L1 expression (Green et al., 2010 & Rui et al., 2010). In another study, 
alternative oncogenic functions were implicated for the 9p24 amplicon based on STAT-
independent epigenetic functions of JAK2. In this study, JAK2 was shown to cooperate with 
the epigenetic modifier JMJDC2 in several lymphoma cell lines positive for the 9p24 gain to 
induce epigenetic remodeling of the oncogene MYC locus leading to altered expression of 
MYC (Rui et al., 2010). The cooperative interplay between JAK2 and JMJDC2 was further 
demonstrated when the anti-proliferative effects induced by loss of JMJD2C were 
exaggerated upon JAK inhibition. In addition, inactivating mutations in SOCS-1, a negative 
regulator of JAK-STAT signaling are observed in 40% of cHL patients (Weniger et al., 2006 & 
Mottok et al., 2007). Increased expression of activated STATs, namely STAT 3 and STAT6 
are often observed in cHL patients and this is thought to be due to sustained signaling loops 
perpetuated by chronic IL-13 stimulation (Skinnider et al., 2002) furthermore, loss of STAT3 
or STAT6 in cHL cell lines results in diminished proliferative capacity and induction of 
apoptosis (Baus, 2009 & Kube et al., 2005). To further validate a role for abnormal JAK-STAT 
signaling in lymphoma-type cancers is the more recent study in which an inverse 
relationship between the inhibitory microRNA-135a and JAK2 was observed in cHL 
patients. Interestingly, low levels of miR-135a expression were strongly correlated with 
disease relapse and shorter disease-free survival in a cohort of cHL patients. The regulatory 
role of miR-135a on JAK2 was confirmed when over- expression of miR-135a led to an 
increase in JAK2 expression (25%-55%) in lymphoma cell lines (Navarro et al., 2009).  
5.2 Role of dysregulated JAK-STAT signaling in multiple myeloma 
Altered JAK-STAT signaling has also been implicated in the progression of multiple 
myeloma (MM). MM is an aggressive hematological malignancy characterized by excessive 
proliferation of clonal plasma B-cells that accumulate in the bone marrow (Anderson et al., 
1999). The maintenance of MM is highly dependent on the interaction of myeloma cells with 
resident bone marrow stromal cells (BMSC) both of which secrete various cytokines and 
growth factors that promote myeloma cell growth. IL-6 is recognized as a critical cytokine 
that’s essential for the survival and proliferation of myeloma cells (Bommert et al., 2006). 
Elevated serum levels of IL-6 are frequently observed in MM patients who fail to respond to 
conventional chemotherapies and IL-6 levels also correlate with poor prognosis of MM 
(Niesvizky et al., 1995). IL-6 signals through JAK1/JAK2/TYK2 leading to downstream 
activation of STAT3 to promote proliferation and survival of myeloma cells (Murray et al., 
2007). Interestingly, elevated levels of activated STAT3 have been observed in more than 
50% of myeloma patient samples (Bharti AC et al., 2004). Pre-clinical studies have shown 
that JAK inhibition can induce apoptosis, inhibit proliferation and block constitutive and  
IL-6 induced activation of STAT3 in several MM cell-based models. Furthermore, JAK 
inhibition also enhanced the anti-tumorgenic effects of bortezomib, a current therapy 
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available for MM, in tumor models of myeloma. In summary, JAK inhibition may not be 
sufficient as a mono-therapy for the treatment of MM but studies that combine JAK 
inhibitors with the current treatments available for MM like bortezomib may prove 
beneficial for MM patients. Of note, the pan-JAK inhibitor, INCB18424, currently being 
tested for the treatment of MPN is also being evaluated in a phase I study for the treatment 
of MM.  
5.3 Implications for abnormal JAK-STAT signaling in solid tumors 
Dysregulated JAK-STAT signaling has also been implicated in the pathogenesis of solid 
tumors primarily due to elevated levels of constitutively activated STATs. Among the 
STATs, STAT3 and STAT5 are the most studied and well characterized regarding their 
oncogenic potential. Activated STATs possess multiple oncogenic traits which promote 
tumorgenesis including tumor cell proliferation, induction of anti-apoptotic and immune 
cell responses. A defined role has been established for STAT5 in driving some hematological 
malignancies, including some MPNs where STAT5 expression leads to a MPN-like 
phenotype, while STAT3 appears to be more involved in solid tumor progression (Germain, 
2007). In solid tumors, increased STAT activation is thought to be due to sustained cytokine 
stimulation via autocrine/paracrine signaling loops rather than increased activity in 
upstream activators of STATs such as JAKs. Elevated levels of activated STAT3 are observed 
in multiple solid tumors including breast, prostate, colon, pancreatic, head and neck and 
ovarian cancers (Song et al, 2006 & Frank., 2003) Recently, an extensive profiling study was 
done that identified a subset of solid tumor cell lines that expressed high levels of 
constitutive and IL-6 inducible activated STAT3 and when these cells were treated with 
specific JAK inhibitors both constitutive and inducible STAT3 activation was suppressed 
(Hedvat et al., 2009). In a panel of pancreatic cell lines, elevated activated STAT3 levels were 
found to correlate with gp130 expression, an IL-6 receptor, reinforcing the idea that STAT 
activation in solid tumors is related to sustained cytokine stimulation (Corcoran et al., 2011)  
6. Conclusion 
Emerging clinical data on a variety of JAK2 inhibitors support a role of these agents in the 
symptomatic relief of MPN patients. However, there are still unresolved issues associated 
with these inhibitors including the inability of most inhibitors to reduce the amount of 
mutant allele burden. The numerous mechanisms that blood-derived cancer cells have 
acquired to preferentially activate JAK-STAT signaling (point mutations, translocations & 
chromosomal gains) demonstrates the importance of this pathway in promoting 
hematological malignancies. The use of JAK inhibitors for the treatment of other non-MPN 
hematological cancers such as lymphomas and multiple myelomas are intriguing but 
require additional pre-clinical studies to determine which JAKs underlie these findings. In 
this regard, lymphomas with a high frequency of the 9p24 gain (30%) coupled with the 
recent identification of the novel JAK2-SEC31-A fusion protein implicates a preference for 
these cells to also activate JAK-STAT signaling. In multiple myeloma, a reliance of these cells 
on IL-6 for their survival and growth suggests that these patients could benefit from JAK 
inhibition therapies. For the role of JAK2-STAT signaling in solid tumors, it remains unclear 
of the potential of pathway inhibition but is likely to require rational combination strategies 
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